Ontorpacept, CAS 2131089-46-6

Product Description: Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity[1].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Petrova PS, et al. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clin Cancer Res. 2017 Feb 15;23(4):1068-1079./[2]Petrova PS, et al. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clin Cancer Res. 2017 Feb 15;23(4):1068-1079.

CAS Number: 2131089-46-6

Molecular Weight: N/A

Compound Purity: 99.57

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Others

• SKU: MEXHY-P99777-10
• Manufacturer: MedChemExpress
• Manufacturer SKU: HY-P99777-10
• Package Unit: 10 mg
• Quantity Unit: STK
• Conjugate: Unconjugated